BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a protein naturally found in human gastric juice. It is widely studied in preclinical research for its role in tissue repair, angiogenesis, and cytoprotective signalling.

How do I reconstitute BPC-157?

Reconstitute with 1-2 ml of bacteriostatic water. Allow the vial to reach room temperature, inject solvent gently down the inside wall, and swirl gently. Never shake. Store reconstituted solution at 2-8°C and use within 4-6 weeks.

What purity is BioLab's BPC-157?

Every batch is independently tested via HPLC and mass spectrometry to confirm 99%+ purity and correct molecular identity. A batch-specific Certificate of Analysis is available with every order.

How should I store BPC-157?

Store lyophilised vials at -20°C, protected from light and moisture. Once reconstituted with bacteriostatic water, store at 2-8°C and use within 4-6 weeks. Avoid repeated freeze-thaw cycles.

FOX04-DRI 10 mg

£185.00

FOX04-DRI is a D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 interaction. One of the most studied senolytic compounds in ageing biology. Available to buy in the UK from BioLab Peptides – 10 mg, 99%+ purity.

Purity: ≥99% (HPLC & MS)
Quantity: 10 mg per vial
Structure: D-retro-inverso peptide (protease-resistant)
Storage: -20°C (lyophilised) · 2-8°C (reconstituted)

Categories: All Peptides, Anti-Ageing & Longevity

Description
Reviews (0)

FOX04-DRI 10 mg – Senolytic Research Peptide

FOX04-DRI is a D-retro-inverso (DRI) peptide that disrupts the interaction between FOXO4 and p53 in senescent cells. Developed by researchers at Erasmus University Medical Centre (Netherlands), it was published in Cell in 2017 as a selective senolytic, capable of triggering apoptosis specifically in senescent cells while sparing healthy cells.

Research Background

Mechanism: FOXO4-p53 disruption – Senescent cells survive by sequestering the pro-apoptotic protein p53 via FOXO4 binding. FOX04-DRI competitively disrupts this interaction, releasing p53 to trigger mitochondrial apoptosis selectively in senescent cells.

D-retro-inverso design – The DRI modification reverses the peptide backbone chirality, making FOX04-DRI resistant to protease degradation while maintaining binding specificity. This gives it a much longer functional half-life than conventional L-peptides.

Senescent cell clearance – Accumulation of senescent cells is a hallmark of ageing, contributing to chronic inflammation (“inflammaging”), tissue dysfunction, and age-related pathology. Senolytics like FOX04-DRI are studied for their ability to selectively remove these cells.

Ageing phenotype research – Published studies reported improved fitness, fur density, and renal function in aged animal models following FOX04-DRI treatment, driving significant interest in the geroscience community.

Related Products

For complementary longevity research, see Epithalon (telomerase), SS-31 (mitochondria), MOTS-c (metabolism), and GHK-Cu (gene expression). Browse Anti-Ageing & Longevity.